Skip to main content

Peer Review reports

From: Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors

Original Submission
16 Jul 2016 Submitted Original manuscript
22 Aug 2016 Reviewed Reviewer Report - Jiejie Xu
22 Aug 2016 Reviewed Reviewer Report - Samer Tabchi
25 Aug 2016 Reviewed Reviewer Report - Yasuyoshi Miyata
27 Aug 2016 Reviewed Reviewer Report - Arjun kalvala
26 Sep 2016 Author responded Author comments - Hai-Liang Zhang
Resubmission - Version 2
26 Sep 2016 Submitted Manuscript version 2
17 Nov 2016 Author responded Author comments - Hai-Liang Zhang
Resubmission - Version 3
17 Nov 2016 Submitted Manuscript version 3
1 Dec 2016 Author responded Author comments - Hai-Liang Zhang
Resubmission - Version 4
1 Dec 2016 Submitted Manuscript version 4
12 Dec 2016 Author responded Author comments - Hai-Liang Zhang
Resubmission - Version 5
12 Dec 2016 Submitted Manuscript version 5
Publishing
16 Dec 2016 Editorially accepted
5 Jan 2017 Article published 10.1186/s12885-016-3016-4

You can find further information about peer review here.

Back to article page